Expertise in
1
conditions

Tobias W. Holderried

Bonn, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Bonn, NW, DE 

Overview

Tobias Holderried practices practicing medicine in Bonn, Germany.

Mr. Holderried is highly rated in 1 condition, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Bonn, NW, Germany
Other Locations
Aachen, NW, Germany
Duesseldorf, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: May 13, 2026
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Diagnostic test, Biological
Study Drugs: IMA201, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor
A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

51 Total Publications

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026

Frequently Asked Questions about Tobias W. Holderried

Is Tobias W. Holderried a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Tobias W. Holderried is classified as an Advanced expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tobias W. Holderried participate in research or clinical trials?

Yes. Tobias W. Holderried has published 51 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Tobias W. Holderried's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Holderried's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile